

BC Cancer Protocol Summary for Treatment of Elderly Newly Diagnosed Glioma Patient with Concurrent and Adjuvant Temozolomide and Radiation Therapy

Protocol Code

CNELTZRT

Tumour Group

Neuro-Oncology

Contact Physician

Dr. Rebecca Harrison

ELIGIBILITY:

Patients must have:

- Newly diagnosed malignant gliomas (grade 3 or 4), and
- Age greater than 70 (elderly), or
- Age 60 to 69 (younger) but ineligible for CNAJ TZRT or poor performance status (e.g., ECOG 2 to 3)

Patients should have:

- ECOG 0-2
- Adequate renal and hepatic function

CAUTION:

- Significant hepatic dysfunction

TESTS:

- Baseline and before starting adjuvant temozolomide: CBC & Diff, ALT, total bilirubin, creatinine, random glucose (patients on dexamethasone)
- During concomitant temozolomide with RT (dual modality):
 - Weekly CBC & Diff for 4 weeks
 - Prior to Week 4: ALT, total bilirubin, random glucose
- Before each treatment of adjuvant temozolomide:
 - Day 1: CBC & Diff, ALT, total bilirubin, random glucose
 - Day 22: CBC & Diff
- Before cycles #3 and 5 and at completion of adjuvant temozolomide: neuroimaging
- If clinically indicated: sodium, potassium, magnesium, calcium, creatinine

PREMEDICATIONS:

- For concomitant temozolomide with RT (dual modality): ondansetron 8 mg given 30 minutes prior to first dose of temozolomide, then prochlorperazine 10 mg po 30 minutes prior to each subsequent dose of temozolomide
- For adjuvant temozolomide: ondansetron 8 mg po 30 minutes prior to each dose of temozolomide

TREATMENT:

Drug	Dose*	BC Cancer Administration Guideline
temozolomide	Concomitant with RT: 75 mg/m ² daily preferably 1 h prior to RT especially in the first week of treatment, and in A.M. on days without RT until completion of RT (usual duration 3 weeks) If Indicated: Adjuvant treatment starting 4 wks after RT: 150 mg/m ² once daily x 5 d (d 1 to 5) every 28 d x 6 cycles	PO

* refer to [Temozolomide Suggested Capsule Combination Table](#) for dose rounding

- Dose may be increased to 200 mg/m² for the second cycle of adjuvant therapy if no significant hematologic, hepatic or other toxicity is noted (see below)
- Trimethoprim/sulfamethoxazole DS one tablet po q Monday, Wednesday and Friday is recommended for patients on concomitant or adjuvant temozolomide if requiring dexamethasone for longer than 4 weeks
- Discontinue for clinical or radiographic progression.

DOSE MODIFICATIONS:

1. Hematological

For Concomitant Temozolomide with RT

Weekly CBC:

ANC ($\times 10^9/L$)		Platelets ($\times 10^9/L$)	Dose
greater than or equal to 1.5	and	greater than or equal to 100	100%
1.0 to less than 1.5	or	75 to less than 100	Delay temozolomide until counts recover
less than 1.0	or	less than 75	Discontinue temozolomide

For Adjuvant Temozolomide

Day 1:

ANC ($\times 10^9/L$)		Platelets ($\times 10^9/L$)	Dose
greater than or equal to 1.5	and	greater than or equal to 100	100%
less than 1.5	or	less than 100	Delay*

* Follow CBC weekly and re-institute temozolomide at one dose level lower (150 mg/m^2 or 100 mg/m^2) if ANC recovers to greater than $1.5 \times 10^9/L$ and platelets recover to greater than $100 \times 10^9/L$ within 3 weeks

Day 22:

ANC ($\times 10^9/L$)		Platelets ($\times 10^9/L$)	Dose
greater than or equal to 1.0	and	greater than or equal to 50	100%
less than 1.0	or	less than 50	Reduce one dose level**

**Dose levels are 200 mg/m^2 , 150 mg/m^2 and 100 mg/m^2

- Note: Dose reductions below 100 mg/m^2 are not permitted. Temozolomide should be discontinued for repeat grade 3 or 4 hematologic toxicity (ANC less than $1 \times 10^9/L$, platelets less than $50 \times 10^9/L$) at the 100 mg/m^2 dose.

2. Hepatic Dysfunction

For Concomitant Temozolomide with RT

Bilirubin (micromol/L)		ALT	Dose
less than 25	and	less than or equal to 2.5 x ULN	100%
greater than or equal to 25	or	greater than 2.5 x ULN	Delay***

*** Follow LFTs weekly and re-institute temozolomide at 75 mg/m² if Bilirubin recovers to less than 25 micromol/L and ALT recovers to less than or equal to 2.5 x ULN

Note: Dose reductions below 75 mg/m² are not permitted. Radiation Therapy to continue without temozolomide until recovery of LFTs.

For Adjuvant Temozolomide

Bilirubin (micromol/L)		ALT	Dose
less than 25	and	less than or equal to 2.5 x ULN	100%
25-85	or	2.6 – 5 x ULN	Reduce one dose level**
greater than 85	or	greater than 5 x ULN	Delay***

** Dose levels are 200 mg/m², 150 mg/m² and 100 mg/m²

*** Follow LFTs weekly and re-institute temozolomide at 100 mg/m² if Bilirubin recovers to less than 85 micromol/L and ALT recovers to less than 5 x ULN

- Note: Dose reductions below 100 mg/m² are not permitted. Temozolomide should be discontinued for repeat Bilirubin greater than 85 micromol/L and repeat ALT greater than 5 x ULN

PRECAUTIONS:

1. **Neutropenia:** Fever or other evidence of infection must be assessed promptly and treated aggressively.
2. **Thrombocytopenia:** Day 22 platelet counts less than $50 \times 10^9/L$ should be monitored at least twice weekly until recovering. Platelet counts less than $20 \times 10^9/L$ and falling should be treated with platelet transfusion.
3. **Pneumocystis Jiroveci (previously Carinii) pneumonia (PJP):** Occasional reports of PJP in patients receiving concomitant or adjuvant Temozolomide have occurred. Prophylaxis as described above is recommended for patients receiving Temozolomide.
4. **Renal Dysfunction:** Renal impairment is not expected to affect temozolomide clearance. Caution should be exercised when treating patients with creatinine clearance less than 36 mL/min.

Call Dr. Rebecca Harrison or tumour group delegate at (604) 877-6000 or 1-800-663-3333 with any problems or questions regarding this treatment program.

References:

1. Perry, JR, Laperriere N, O'Callaghan CJ, et al. A phase III randomized controlled trial of short-course radiotherapy with or without concomitant and adjuvant temozolomide in elderly patients with glioblastoma. J Clin Oncol 2016;34: LBA2 (Abstr).
2. Sandhu G, Adattini J, Armstrong Gordon E, O'Neill N. On behalf of the ADDIKD Guideline Working Group. International consensus guideline on anticancer drug dosing in kidney dysfunction. 2022. eviQ, Cancer Institute NSW. St Leonards, Australia.